Replies to post #117881 on Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

Agreee on the “sweet spot”. My reasoning that 450 mg/m2 is not the optimal dosage is because Kevetrin is still extremely well-tolerated at 750 mg/m2. So I believe there’ll be a greater benefit in cohort 11. There’s a reason why management is pushing for 750 instead of stopping at 450. Hopefully we’ll find out soon.

“We have found Kevetrin to be extremely well-tolerated, including in one patient who received their first treatment at 750 mg/m2 – the highest dose yet administered and is 75x the initial study dose.”

http://cellceutix.com/cellceutix-reports-results-for-quarter-ended-march-31-2015-enrollment-for-oral-mucositis-studies-to-begin-this-month/#sthash.05hkwseI.dpbs

Kevetrin will have a "sweet spot" that it performs best at.